Background and aims: Amenorrhea often occurs during chemotherapy and it may reduce fertility and cause menopausal symptoms.The purpose of this study was to determine the incidence of CT-related amenorrhea (CRA) among breast cancer patients following adjuvant chemotherapy and the influence of their BMI. Methods: In this retrospective study we evaluated 18 PBC patients (pts), 43 median age years, treated with 6 cycles of adjuvant anthracycline-cyclophosphamide. BMI was evaluated in all women. Overall population (OP) had regular menstrual cycle (MC) and nobody began hormone therapy, at the same time. Results: Fifteen pts (83%) experienced amenorrhea during CT; the interruption of MC appeared during the first three cycles of CT in about 67% of pts and particularly 4 pts (27%) after 1 cycle, 4 pts (27%) after 2 cycles, 2 pts (13%) after 3 cycles e 5 pts (33%) in subsequent cycles. In OP, 14 pts (78%) had BMI<24.9 and 4 pts (22%) had BMI>25. MC reappeared at the end of CT in only 2 pts (13%), with a median age of 43 years and BMI<24.9. Three pts (17%) have not amenorrhea during CT; the median age was 34 years and BMI<24.9. Conclusions: In our small experience CRA occurs very frequently. Its incidence and persistence was higher in patients older than 40 years than in younger patients. BMI did not influence occurrence of amenorrhea.
BODY MASS INDEX (BMI) AND AMENORRHEA IN PREMENOPAUSAL BREAST CANCER PATIENTS (PBC) TREATED WITH ADJUVANT ANTRACYCLINE AND CYCLOPHOSPAMIDE CHEMOTHERAPY (CT) / Zaccarelli, Eleonora; Rossi, Luigi; Tomao, Federica; Giordani, Erika; Verrico, Monica; Strudel, Martina; PERRONE CONGEDI, Francesca; Papa, Anselmo; Caruso, Davide; Capalbo, Carlo; Rinaldi, G; Bianchi, L; Lo Russo, G; Spinelli, Gp; Prete, A; Stati, Valeria; Evangelista, S; Tomao, Silverio. - In: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. - ISSN 1048-891X. - STAMPA. - 24:(2014), pp. 18-19. (Intervento presentato al convegno 3rd Regional IGCS Meeting 2014 tenutosi a Cape Town, South Africa nel May 16-18, 2014).
BODY MASS INDEX (BMI) AND AMENORRHEA IN PREMENOPAUSAL BREAST CANCER PATIENTS (PBC) TREATED WITH ADJUVANT ANTRACYCLINE AND CYCLOPHOSPAMIDE CHEMOTHERAPY (CT)
ZACCARELLI, ELEONORA;ROSSI, Luigi;TOMAO, FEDERICA;GIORDANI, ERIKA;VERRICO, MONICA;STRUDEL, MARTINA;PERRONE CONGEDI, FRANCESCA;PAPA, ANSELMO;CARUSO, DAVIDE;CAPALBO, CARLO;Rinaldi, G;STATI, VALERIA;TOMAO, SILVERIO
2014
Abstract
Background and aims: Amenorrhea often occurs during chemotherapy and it may reduce fertility and cause menopausal symptoms.The purpose of this study was to determine the incidence of CT-related amenorrhea (CRA) among breast cancer patients following adjuvant chemotherapy and the influence of their BMI. Methods: In this retrospective study we evaluated 18 PBC patients (pts), 43 median age years, treated with 6 cycles of adjuvant anthracycline-cyclophosphamide. BMI was evaluated in all women. Overall population (OP) had regular menstrual cycle (MC) and nobody began hormone therapy, at the same time. Results: Fifteen pts (83%) experienced amenorrhea during CT; the interruption of MC appeared during the first three cycles of CT in about 67% of pts and particularly 4 pts (27%) after 1 cycle, 4 pts (27%) after 2 cycles, 2 pts (13%) after 3 cycles e 5 pts (33%) in subsequent cycles. In OP, 14 pts (78%) had BMI<24.9 and 4 pts (22%) had BMI>25. MC reappeared at the end of CT in only 2 pts (13%), with a median age of 43 years and BMI<24.9. Three pts (17%) have not amenorrhea during CT; the median age was 34 years and BMI<24.9. Conclusions: In our small experience CRA occurs very frequently. Its incidence and persistence was higher in patients older than 40 years than in younger patients. BMI did not influence occurrence of amenorrhea.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
